ELVN-001 shows cancer-killing potential in Phase 1 CML study
ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…
Blood cancer
EU committee recommends fixed-duration Calquence combo for CLL
A European regulatory committee has recommended approval of a fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) for adults with previously untreated chronic lymphocytic leukemia…
Blocking LSD1, GSK3 could be treatment strategy for AML
Simultaneously blocking the activity of two proteins, LSD1 and GSK3, may be an effective strategy to treat acute myeloid leukemia (AML), an aggressive type of…
AML World Awareness Day April 21 to spotlight rare blood cancer
April 21 marks AML World Awareness Day — a global effort to boost recognition of acute myeloid leukemia (AML) and raise funds for research…
Phase 1 trial of STX-0712 for rare leukemia CMML doses first patient
The first patient has been dosed in a Phase 1 clinical trial evaluating the safety and early efficacy of STX-0712 in people with resistant or…
Exportin-1 function may explain blood cancer treatment side effects
Exportin-1, a therapeutic target for nuclear export inhibitors — a class of drugs used to treat blood cancers including multiple myeloma and leukemia…
Phase 3 CLL/SLL trial of ICP-248 plus orelabrutinib doses first patient
The first patient has been dosed in a Phase 3 clinical trial testing ICP-248 (mesutoclax) in combination with orelabrutinib in adults with chronic lymphocytic leukemia…
Orca-T outperforms standard stem cell transplant for blood cell cancer
Orca-T, Orca Bio‘s investigational allogeneic stem cell transplant for treating blood cell cancers, more than doubled the rate of survival free from moderate…
Treatment, outcomes poorer in AML with chromosome abnormality
Chromoanagenesis — an abnormal rearrangement of DNA within the chromosomes of certain cells, including blood cells — links with limited treatment response and poorer outcomes…
Olverembatinib named ALL breakthrough therapy in China
China has granted breakthrough therapy designation to olverembatinib to be used with low-intensity chemotherapy as a first-line treatment for newly diagnosed people with Philadelphia chromosome-positive…
